Novo Nordisk A/S said it retains about 60% of the list price of Ozempic and Wegovy in the US after rebates and fees paid to middlemen, as the debate heats up over the cost of its blockbuster diabetes and obesity medicines.
Originally posted 2024-05-28 12:03:05.
